Recently the Institute of Cancer Research, London, in partnership with the Royal Marsden NHS Foundation Trust, demonstrated compelling results in an early-stage ovarian cancer clinical trial. A combination of targeted therapies directed toward a specific type of ovarian cancer shrinks cancerous tumors in half of the patients involved in the study. By blocking signals cancer cells need to grow, the combination of drugs might portend a novel treatment for women with an uncommon ovarian cancer that rarely responds well to chemotherapy or hormone therapy. In the 25 patient Phase 1 FRAME trial, clinical investigational teams at both ICR London and the Royal Marsden NHS Foundation Trust investigated the safety and efficacy of VS-6766 and defactinib in low-grade serous ovarian cancer. The result? Nearly half (46%) of the patients experienced a significant decline in tumor size thanks to this investigational combination treatment. However, for those patients with the KRAS mutation, the results were significantly better—64% of these patients experienced a marked decline in tumor size.
Low-Grade Serous Ovarian Cancer
An uncommon form of cancer that typically develops at a younger age...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).